Other News To Note
Tuesday, February 15, 2011
Idera Pharmaceuticals Inc., of Cambridge, Mass., said preclinical data showed that IMO-3100, an antagonist of Toll-like receptor 7 and TLR9, suppressed several key disease progression parameters in a model of lupus. The data, presented at the Dendritic Cells and Initiation of Adaptive Immunity Keystone Symposia, in Santa Fe, N.M., showed that IMO-3100 treatment led to a dose-dependent reduction in serum anti-DNA antibody levels, BUN levels and urine protein levels in NZBW/F1 mice.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.